Sorin CRM: Cracking the US Market

Sorin's history of important technology breakthroughs has long been one of the best kept secrets in the cardiac rhythm management market. The company is now restructuring to focus on CRM, particularly in the US, and challenge the major players on their home turf.

While large-scale consolidation has occurred in several major medical device markets, it has generally tended to serve different purposes in each industry segment. In orthopedics, a handful of large deals, most notably Stryker’s purchase of Howmedica and Johnson & Johnson’s acquisition of DePuy, took a highly fragmented market (in terms of market share) and created a much more concentrated one, connecting commercial success to critical mass. In interventional cardiology, on the other hand, consolidation has tended to give companies wishing to build bigger franchises the technology and market footprint they needed—think of Boston Scientific’s acquisition of SciMed LifeSystems or Medtronic’s purchase of AVE.

No industry sector more clearly exhibits the sustained dynamics of consolidation than the cardiac rhythm management (CRM) market. But consolidation...

More from Business Strategy

More from In Vivo